AMAG Pharmaceuticals

AMAG is a biopharmaceutical company focused on bringing therapeutics to market that provide clear benefits and help improve people’s lives. Its products support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR, the Company also helps families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine.


Type
Public
HQ
Waltham, US
Founded
1981
Size (employees)
545 (est)-1%
AMAG Pharmaceuticals was founded in 1981 and is headquartered in Waltham, US

AMAG Pharmaceuticals Office Locations

AMAG Pharmaceuticals has offices in Waltham, Tucson and San Bruno
Waltham, US (HQ)
1100 Winter St
San Bruno, US
1200 Bayhill Dr
Tucson, US
6550 S Bay Colony Dr

AMAG Pharmaceuticals Data and Metrics

AMAG Pharmaceuticals Financial Metrics

AMAG Pharmaceuticals's revenue was reported to be $139 b in Q1, 2017
USD

Revenue (Q1, 2017)

139 b

Gross profit (Q1, 2017)

134 b

Gross profit margin (Q1, 2017), %

96%

Net income (Q1, 2017)

(36.6 b)

EBIT (Q1, 2017)

(40 b)

Market capitalization (25-Jul-2017)

685.8 m

Cash (31-Mar-2017)

252.9 m
AMAG Pharmaceuticals's current market capitalization is $685.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

80.9 m124.4 m418.3 m532.1 m

Revenue growth, %

54%236%27%

Cost of goods sold

12 m20.3 m10 m20.6 m

Gross profit

68.9 m104.1 m408.3 m511.5 m

Gross profit Margin, %

85%84%98%96%

R&D expense

66.1 m

General and administrative expense

249.9 m

Operating expense total

80.5 m107.9 m297.1 m453.2 m

EBIT

(7.6 m)(3.8 m)111.2 m78.9 m

EBIT margin, %

(9%)(3%)27%15%

Interest expense

(14.7 m)(53.3 m)(73.2 m)

Interest income

3.1 m

Pre tax profit

(9.6 m)9.1 m

Income tax expense

153.2 m7.1 m11.5 m

Net Income

(9.6 m)135.8 m32.8 m(2.5 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

24.8 m25.5 m89.5 m123.9 m96.2 m109.3 m127.4 m143.8 m139 b

Cost of goods sold

2.7 m3 m21 m19.7 m3.3 m5.5 m5.2 m5 m5 b

Gross profit

22.1 m22.5 m68.5 m104.2 m92.9 m103.8 m122.2 m138.8 m134 b

Gross profit Margin, %

89%88%77%84%97%95%96%97%96%

R&D expense

4.5 m5.4 m7 m8.2 m19.8 m14.2 m14.2 m17.1 m16.5 b

General and administrative expense

16.3 m12.9 m32.1 m31.8 m46.1 m63.2 m51.9 m57.2 m70.4 b

Operating expense total

20.8 m18.2 m39.1 m40 m66 m77.4 m66.2 m74.3 m86.9 b

EBIT

1.2 m4.3 m28.8 m61.1 m(1.4 m)7.4 m18.1 m38.8 m(40 b)

EBIT margin, %

5%17%32%49%(1%)7%14%27%(29%)

Interest expense

(3.1 m)(3.1 m)(10.4 m)(10.2 m)(14.2 m)(18.4 m)(18.3 m)(18.3 m)(18.3 b)

Pre tax profit

21.3 m(57.3 b)

Income tax expense

5.6 m18 m14.1 m(2.5 m)1.2 m5.1 m(20.7 b)

Net Income

(1.5 m)1.5 m12.9 m33.3 m(20.6 m)(7.5 m)(596 k)16.2 m(36.6 b)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

27 m119.3 m228.7 m274.3 m

Accounts Receivable

6.8 m38.2 m85.7 m92.4 m

Inventories

17.2 m40.6 m40.6 m37.3 m

Current Assets

244.4 m274 m606.7 m718.6 m

PP&E

1.8 m1.5 m28.7 m24.5 m

Goodwill

205.8 m639.2 m639.5 m

Total Assets

265.5 m1.4 b2.5 b2.5 b

Accounts Payable

2.6 m7.3 m4.9 m3.7 m

Total Debt

21.2 m

Current Liabilities

33.1 m166.5 m245.9 m312.9 m

Total Liabilities

1.5 b

Additional Paid-in Capital

641.9 m793.8 m1.2 b1.2 b

Retained Earnings

(466.3 m)(330.4 m)(297.7 m)(300.1 m)

Total Equity

172.4 m460 m932.3 m934.4 m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.5 x3 x2.7 x2.7 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

202.1 m196.2 m243.8 m89.9 m167.5 m203.4 m251.1 m305.3 m252.9 m

Accounts Receivable

10.6 m10.9 m56.2 m58 m73.7 m82.8 m66.1 m70.1 m85.2 m

Inventories

22 m19.6 m35.9 m34.4 m37.2 m42 m39.6 m38.2 m36.9 m

Current Assets

424.1 m427 m519.5 m555.5 m655.4 m622.2 m665.6 m736.8 m688.9 m

PP&E

1.7 m1.6 m1.4 m1.9 m30.4 m27.9 m27.2 m25.3 m22.7 m

Goodwill

205.8 m204.4 m637.4 m639.5 m639.5 m639.5 m639.5 m

Total Assets

448.8 m451.4 m1.6 b1.6 b2.6 b2.5 b2.5 b2.5 b2.4 b

Accounts Payable

3.5 m1.9 m6 m6.1 m3.7 m3.4 m8.7 m4.7 m7.6 m

Current Liabilities

37.2 m38.8 m166.6 m324 m266.8 m248.6 m297.1 m328.9 m307.9 m

Additional Paid-in Capital

670.9 m673.8 m992 m1 b1.2 b1.2 b1.2 b1.2 b1.2 b

Retained Earnings

(474.9 m)(473.5 m)(317.5 m)(284.3 m)(304.9 m)(305.2 m)(305.8 m)(289.6 m)(315.2 m)

Total Equity

193 m197 m671.2 m713 m920 m923 m916.2 m938 m924.1 m

Financial Leverage

2.3 x2.3 x2.4 x2.3 x2.8 x2.7 x2.7 x2.7 x2.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(9.6 m)135.8 m32.8 m(2.5 m)

Depreciation and Amortization

3.1 m7 m69.1 m99.9 m

Accounts Receivable

(432 k)3.6 m(37 m)(9.9 m)

Inventories

(1 m)(1.4 m)(5.2 m)(2.4 m)

Accounts Payable

(5.7 m)10.7 m7.9 m49 m

Cash From Operating Activities

(6.8 m)11.4 m96 m246.2 m

Capital Expenditures

(1.6 m)(147 k)(5.5 m)

Cash From Investing Activities

(13.9 m)(432.9 m)(899 m)(72.7 m)

Cash From Financing Activities

1.4 m513.8 m912.5 m(127.9 m)

Interest Paid

28 m62.4 m

Income Taxes Paid

2.4 m5.3 m

Free Cash Flow

(5.1 m)11.6 m240.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.5 m)1.5 m12.9 m33.3 m(20.6 m)(7.5 m)(596 k)16.2 m(36.6 b)

Depreciation and Amortization

19.6 m

Accounts Receivable

10.6 m10.9 m56.2 m58 m73.7 m2.9 m66.1 m70.1 m85.2 m

Inventories

22 m19.6 m35.9 m34.4 m37.2 m(2.2 m)39.6 m38.2 m36.9 m

Accounts Payable

3.5 m1.9 m6 m6.1 m3.7 m(6.6 m)8.7 m4.7 m7.6 m

Cash From Operating Activities

26.6 m

Cash From Investing Activities

(38.6 m)

Cash From Financing Activities

(13.3 m)

Interest Paid

28 m

Income Taxes Paid

2.4 m
USDY, 2017

Revenue/Employee

255 m

Financial Leverage

2.6 x

AMAG Pharmaceuticals Market Value History

AMAG Pharmaceuticals Company Life and Culture

You may also be interested in